RKVT.F logo

Rakovina Therapeutics Inc.OTCPK:RKVT.F Stock Report

Market Cap US$1.9m
Share Price
n/a
1Y-80.8%
7D22.4%
1D22.4%
Portfolio Value
​
View

Rakovina Therapeutics Inc.

OTCPK:RKVT.F Stock Report

Market Cap: US$1.9m

Rakovina Therapeutics (RKVT.F) Stock Overview

A biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. More details

RKVT.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Risk Analysis

Earnings have declined by 22.7% per year over past 5 years

Negative shareholders equity

Makes less than USD$1m in revenue (CA$0)

Highly volatile share price over the past 3 months compared to the US market

+ 2 more risks

RKVT.F Community Fair Values

Create Narrative

See what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW480,485 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
480,485 investors already sharing narratives
View all narratives

Rakovina Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rakovina Therapeutics
Historical stock prices
Current Share PriceCA$0.09
52 Week HighCA$0.49
52 Week LowCA$0.04
Beta-0.21
1 Month Change-7.65%
3 Month Change14.36%
1 Year Change-80.81%
3 Year Changen/a
5 Year Changen/a
Change since IPO-85.00%

Recent News & Updates

Recent updates

Shareholder Returns

RKVT.FUS BiotechsUS Market
7D22.4%-0.5%-2.0%
1Y-80.8%29.7%15.1%

Return vs Industry: RKVT.F underperformed the US Biotechs industry which returned 29.7% over the past year.

Return vs Market: RKVT.F underperformed the US Market which returned 15.1% over the past year.

Price Volatility

Is RKVT.F's price volatile compared to industry and market?
RKVT.F volatility
RKVT.F Average Weekly Movement74.2%
Biotechs Industry Average Movement10.1%
Market Average Movement7.1%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: RKVT.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RKVT.F's weekly volatility has increased from 40% to 74% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aKim Oishiwww.rakovinatherapeutics.com

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR–mTOR inhibitor drug candidates.

Rakovina Therapeutics Inc. Fundamentals Summary

How do Rakovina Therapeutics's earnings and revenue compare to its market cap?
RKVT.F fundamental statistics
Market capUS$1.91m
Earnings (TTM)-US$5.81m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.3x
P/E Ratio

Is RKVT.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RKVT.F income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$8.18m
Earnings-CA$8.18m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-539.8%

How did RKVT.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/24 10:23
End of Day Share Price 2026/07/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rakovina Therapeutics Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander RihaneFirst Berlin Equity Research GmbH